Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 3/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.61 |
| ▸ | NPY2R | P49146 | 3/20 | 0.61 |
| ▸ | NPY4R | P50391 | 3/20 | 0.61 |
| ▸ | GHSR | Q92847 | 9/20 | 0.61 |
| ▸ | MC5R | P33032 | 1/20 | 0.59 |
| ▸ | MC3R | P41968 | 1/20 | 0.59 |
| ▸ | MC1R | Q01726 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359331 | 1.00 | KISS1R (0.64) | KISS1RMC4RNPY1RNPY2RNPY4R | |
| SCHEMBL26006253 | 1.00 | KISS1R (0.64) | KISS1RMC4RNPY1RNPY2RNPY4R | |
| SCHEMBL29357687 | 0.88 | KISS1R (0.62) | KISS1RMC4RMC5RMC3RMC1R | |
| SCHEMBL29398150 | 0.85 | KISS1R (0.65) | KISS1RMC4RGHSR | |
| SCHEMBL29399016 | 0.84 | GHSR (0.68) | KISS1RNPY1RNPY2RNPY4RGHSR | |
| SCHEMBL12094756 | 0.83 | CCKBR (0.56) | KISS1RNPY1RNPY2RNPY4RGHSR | |
| SCHEMBL29402231 | 0.83 | GHSR (0.69) | KISS1RNPY1RNPY2RNPY4RGHSR | |
| SCHEMBL23152931 | 0.83 | MC4R (0.71) | MC4RGHSR | |
| SCHEMBL28940915 | 0.83 | MC4R (0.71) | MC4RGHSR | |
| SCHEMBL23483109 | 0.83 | MC4R (0.71) | MC4RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255864-A1 | NOVEL COMPOSITIONS COMBINING HEMP DERIVATIVES AND AT LEAST ONE PEPTIDE AND USE THEREOF | FRANCE COSMEPHYL-LAB (FR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255864-A1 | NOVEL COMPOSITIONS COMBINING HEMP DERIVATIVES AND AT LEAST ONE PEPTIDE AND USE THEREOF | CNR2, S100A8, CPA3 | KISS1R 517/4885MC4R 57/4885NPY1R 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.